|
|
|
|
Vol. 62, Issue 4, 795-805, October 2002
Department of Research and Development, BIAL, S. Mamede do
Coronado, Portugal (M.J.B., D.A.L., P.S.S.); Instituto de Tecnologia
Química e Biológica-Universidade Nova de Lisboa, Oeiras,
Portugal (M.A., M.L.R., P.M.M., M.A.C.); and Instituto de Biologia
Experimental e Tecnológica, Oeiras, Portugal (M.A., M.L.R.)
Catechol-O-methyltransferase (COMT; E.C. 2.1.1.6) is a
ubiquitous enzyme in nature that plays an important role in the
metabolism of catechol neurotransmitters and xenobiotics. In
particular, inactivation of drugs such as
L-3,4-dihydroxyphenylalanine (L-DOPA) via
O-methylation is of relevant pharmacological importance,
because L-DOPA is currently the most effective drug used in
the treatment of Parkinson's disease. This justified the interest in
developing COMT inhibitors as potential adjuncts to L-DOPA
therapy. The kinetics of inhibition by BIA 3-335 (1-[3,4-dihydroxy-5-nitrophenyl]-3-(N-3'-trifluormethylphenyl)-piperazine-1-propanone dihydrochloride) were characterized using recombinant rat soluble COMT.
BIA 3-335 was found to act as a potent, reversible, tight-binding inhibitor of COMT with a Ki of 6.0 ± 1.6 nM and displaying a competitive inhibition toward the substrate
binding site and uncompetitive inhibition toward the
S-adenosyl-L-methionine (SAM) binding site. The 2.0-Å resolution crystal structure of COMT in complex with its
cosubstrate SAM and a novel inhibitor BIA 3-335 shows the atomic
interactions between the important residues at the active site and the
inhibitor. This is the first report of a three-dimensional structure
determination of COMT complexed with a potent, reversible, and
tight-binding inhibitor that is expected to have therapeutic applications.
This article has been cited by other articles:
![]() |
M. Grana, A. Haouz, A. Buschiazzo, I. Miras, A. Wehenkel, V. Bondet, W. Shepard, F. Schaeffer, S. T. Cole, and P. M. Alzari The crystal structure of M. leprae ML2640c defines a large family of putative S-adenosylmethionine-dependent methyltransferases in mycobacteria Protein Sci., September 1, 2007; 16(9): 1896 - 1904. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Palma, M. L. Rodrigues, M. Archer, M. J. Bonifacio, A. I. Loureiro, D. A. Learmonth, M. A. Carrondo, and P. Soares-da-Silva Comparative Study of ortho- and meta-Nitrated Inhibitors of Catechol-O-methyltransferase: Interactions with the Active Site and Regioselectivity of O-Methylation Mol. Pharmacol., July 1, 2006; 70(1): 143 - 153. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. H. Cotton, B. Stoddard, and W. W. Parson Oxidative Inhibition of Human Soluble Catechol-O-methyltransferase J. Biol. Chem., May 28, 2004; 279(22): 23710 - 23718. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Palma, M. J. Bonifacio, A. I. Loureiro, L. C. Wright, D. A. Learmonth, and P. Soares-da-Silva Molecular Modeling and Metabolic Studies of The Interaction of Catechol-O-Methyltransferase and a New Nitrocatechol Inhibitor Drug Metab. Dispos., March 1, 2003; 31(3): 250 - 258. [Abstract] [Full Text] [PDF] |
||||